Pacer Advisors
SPRY icon

Pacer Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Pacer Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-485
Closed -$4.13K – 2687
2024
Q2 		$4.13K Sell
485
-31
-6% -$275 ﹤0.01% 3651
2024
Q1 		$5.27K Buy
+516
New +$3.85K ﹤0.01% 3591

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Pacer Advisors's SPRY Position: Q3 2024 in Review

Pacer Advisors sold out of ARS Pharmaceuticals (SPRY) in Q3 2024, closing a stake of 485 shares — an estimated $4.13K sold.

Pacer Advisors first reported a position in SPRY in Q1 2024 and held it in 2 quarters. The position peaked at $5.27K in Q1 2024. 150 funds tracked by Wall St. Rank hold SPRY as of Q3 2024.

  • Pacer Advisors reported no remaining ARS Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 485 ARS Pharmaceuticals shares in Q3 2024, an estimated $4.13K.
  • Pacer Advisors first reported a position in ARS Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Pacer Advisors's ARS Pharmaceuticals position peaked at $5.27K in Q1 2024.
  • 150 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.